Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

An Epidemiological Study to Assess Performance of Using Healthcare Tools to Understand Genital Herpes Simplex Virus-2 (HSV-2) in Patients ≥ 18 Years of Age in the United States and Europe.

A legfontosabb adatok

Ki végzi
GlaxoSmithKline
Hol
Austin, Boston, Columbus, Fort Worth, Houston, Kansas City, Lawrenceville, Long Beach, Los Angeles, Marietta, Memphis, Miami, Newark, Philadelphia, Plantation, Richmond, San Francisco, Smyrna és St Louis (Egyesült Államok)Mind a 19 helyszín megnézéseMég 5 másik országban, 25 helyszínen
Azonosító
Állapot
Befejeződött
Résztvevők
537 fő vett részt
Kezdés
2021. jún. 9.
Befejezés
2024. márc. 14.
A vizsgálat típusa
Megfigyeléses
A vizsgált kezelések
  • Blood sampling
  • Anogenital lesion swab collection
A regiszteradat frissítve
2025. március 7.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 9 feltétel megnézéseKevesebb

Ki vehet részt

  • Man or woman ≥18 years old
  • Written informed consent obtained from the patient prior to performance of any study-specific procedure
  • History of at least one episode of HSV-2 genital herpes lesions in the 12 months preceding the screening, and seropositive for HSV-2 as determined by Western blot OR PCR-positive for HSV-2 (newly diagnosed patients)
  • Patients who are medically stable in the opinion of the investigator
  • Patients who, in the opinion of the investigator, are able to understand and comply with the study requirements (attend regular telephone calls/study site visits/home visits/self-completion of questionnaires, self-swabbing)
  • Seronegative for HIV, as determined by laboratory testing. Patients documented to be positive to HIV will not be eligible for study participation

Ki nem vehet részt

  • Prior receipt of a vaccine or candidate vaccine containing HSV antigens
  • Other genital tract disorders or sexually transmitted diseases that may interfere with the assessment of the study (as per investigator's judgement)
  • Immunocompromised patients, as per medical history and investigator judgement

Helyszínek itt: Egyesült Államok

Még 5 másik országban, 25 helyszínen

  • Austin, TexasHospital not named in the registry
  • Boston, MassachusettsHospital not named in the registry
  • Columbus, OhioHospital not named in the registry
  • Fort Worth, TexasHospital not named in the registry
  • Houston, TexasHospital not named in the registry
  • Kansas City, MissouriHospital not named in the registry
  • Lawrenceville, GeorgiaHospital not named in the registry
  • Long Beach, CaliforniaHospital not named in the registry
  • Los Angeles, CaliforniaHospital not named in the registry
  • Marietta, GeorgiaHospital not named in the registry
  • Memphis, TennesseeHospital not named in the registry
  • Miami, FloridaHospital not named in the registry
  • Newark, DelawareHospital not named in the registry
  • Philadelphia, PennsylvaniaHospital not named in the registry
  • Plantation, FloridaHospital not named in the registry
  • Richmond, VirginiaHospital not named in the registry
  • San Francisco, CaliforniaHospital not named in the registry
  • Smyrna, GeorgiaHospital not named in the registry
  • St Louis, MissouriHospital not named in the registry

A vizsgálatról

Mit akar kideríteni a vizsgálat

The aim of this study is to assess performance of using healthcare tools to understand genital Herpes Simplex Virus-2 (HSV-2) in patients ≥ 18 years of age in the United States and Europe.

A teljes eredeti leírásKevesebb

More specifically, the study aims to evaluate patient-reported outcome and quality-of-life endpoints as well as the performance study procedures in a decentralised setting. Ultimately, this study will allow generating additional real-world evidence (RWE) on patterns of recurrences and other key parameters.

A vizsgálat csoportja

  • Overall Study Group

    Patients aged 18 years old or above, with HSV-2 genital herpes, who are recruited in specific community settings in the United States and in Europe.

    Kezelés: Blood sampling és Anogenital lesion swab collection

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Descriptive, Prospective, Multi-country, Multicentre Study to Assess Performance of Genital Herpes Simplex Virus-2 (HSV-2) Related Disease Endpoints Based on Patient-reported Health Outcomes, Self-swabbing Collected Via Decentralised Approach in Patients ≥ 18 Years of Age in the United States and Europe.
A regiszteradat frissítve
2025. március 7.